Characteristic | Single-dose albendazole | Single-dose nitazoxanide | Nitazoxanide-albendazole combination | Placebo |
---|---|---|---|---|
G. intestinalis | ||||
No. of infected children | 25 | 21 | 19 | 25 |
No. of children not cured after treatment | 10 | 9 | 11 | 12 |
CR, % (95% CI) | 60.0 | 57.1 | 42.1 | 52.0 |
(39.4–80.6) | (34.1–80.2) | (17.7–66.6) | (31.0–73.0) | |
E. histolytica/E. dispar | ||||
No. of infected children | 23 | 23 | 31 | 22 |
No. of children not cured after treatment | 10 | 9 | 10 | 10 |
CR, % (95% CI) | 56.5 | 60.9 | 67.7 | 54.5 |
(34.6–78.4) | (39.3–82.4) | (50.3–85.2) | (31.9–77.1) | |
B. hominis | ||||
No. of infected children | 35 | 37 | 33 | 49 |
No. of children not cured after treatment | 15 | 16 | 10 | 16 |
CR, % (95% CI) | 57.1 | 56.8 | 69.7 | 67.3 |
(39.9–74.4) | (40.0–73.5) | (53.1–86.2) | (53.7–81.0) | |
E. coli | ||||
No. of infected children | 75 | 82 | 56 | 70 |
No. of children not cured after treatment | 50 | 38 | 27 | 50 |
CR, % (95% CI) | 33.3 | 53.7 | 51.8 | 28.6 |
(22.4–44.3) | (42.6–64.7) | (38.3–65.3) | (17.7–39.4) | |
E. hartmanni | ||||
No. of infected children | 14 | 22 | 18 | 19 |
No. of children not cured after treatment | 5 | 5 | 4 | 7 |
CR, % (95% CI) | 64.3 | 77.3 | 77.8 | 63.2 |
(35.6–93.0) | (58.3–96.3) | (56.5–99.1) | (39.3–87.0) | |
E. nana | ||||
No. of infected children | 24 | 25 | 23 | 35 |
No. of children not cured after treatment | 10 | 9 | 2 | 15 |
CR, % (95% CI) | 58.3 | 64.0 | 91.3 | 57.1 |
(37.1–79.6) | (43.8–84.2) | (78.8–100.0) | (39.9–74.4) | |
C. mesnili | ||||
No. of infected children | 17 | 10 | 6 | 12 |
No. of children not cured after treatment | 4 | 1 | 1 | 5 |
CR, % (95% CI) | 76.5 | 90.0 | 83.3 | 58.3 |
(54.0–99.0) | (67.4–100.0) | (40.5–100.0) | (25.6–91.1) | |
I. bütschlii | ||||
No. of infected children | 5 | 13 | 8 | 11 |
No. of children not cured after treatment | 1 | 2 | 2 | 4 |
CR, % (95% CI) | 80.0 | 84.6 | 75.0 | 63.6 |
(24.5–100.0) | (61.9–100.0) | (36.3–100.0) | (29.7–97.5) |